Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Simon Lichtiger(Mount Sinai Medical Center), Stephan R. Targan(Cedars-Sinai Medical Center), Marion Blank(Janssen (United States)), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Cynthia Guzzo(Janssen (Belgium)), Subrata Ghosh(University College Cork), Long-Long Gao(Janssen (United States)), Stephen B. Hanauer(Northwestern University), Paul Rutgeerts(KU Leuven), Gordon R. Greenberg(University of Toronto), Willem J.S. de Villiers(Stellenbosch University), Remo Panaccione(University of Calgary), Jewel Johanns(Johnson & Johnson (United States)), Christopher Gasink(Janssen (United States))
Cited by 1,136
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k